Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs Heron Therapeutics Inc (HRTX) Price & Performance

Blackrock IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs Heron Therapeutics Inc — how do they compare? Blackrock Inc trades at $1,162.86 (market cap $177.92B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: Blackrock Inc is far larger — about 2894.4× Heron Therapeutics Inc's market cap, and Blackrock Inc pays a 2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

BLKHRTX
Market Cap
$177.92B$61.47M
Volume
641,547
Sector
FinancialsHealth
52-Week High
$1.20K$1.49
52-Week Low
$922.90$0.32
Enterprise Value
$179.02B$168.21M
Dividend Yield
2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

BLK trades at $1,159.09, up 2.45% today, with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with Nvidia and other Wall Street firms, signaling strategic positioning in emerging technology investments.

Outlook remains positive with analyst consensus at Buy (78.79%) and a $1,350 price target, though overbought RSI levels and legal scrutiny over mutual fund practices present near-term risks. The company's expansion into tokenized money market products and sustained dividend payments support long-term growth, but investors should monitor margin pressures and regulatory developments.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX